In most people with neuromyelitis optica spectrum disorder (NMOSD), autoantibodies against aquaporin-4 (AQP4) coordinate a complex series of immune activities that drive the disease. Better understanding of these disease-causing mechanisms may help in efforts to find new treatments for NMOSD patients. These mechanisms were explained in the lecture, “…
AQP4
Enspryng has been approved by the Taiwan Food and Drug Administration for treating people 12 and older who have aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), Chugai Pharmaceutical announced. The import drug license…
Recent Posts
- Should I complain about my NMOSD symptoms or not?
- NMOSD treatment approved in China blocks relapses, study finds
- Probing my spirituality in life with chronic illness and hardship
- New study identifies genetic variants tied to AQP4-positive NMOSD
- Uplizna cuts NMOSD relapse risk, even after using immunosuppressants